Nalbadis Anastasios, Trutschel Marie-Luise, Lucas Henrike, Luetzkendorf Jana, Meister Annette, Mäder Karsten
Department of Pharmaceutical Technology, Faculty of Natural Sciences 1-Biosciences, Martin Luther University Halle-Wittenberg, 06120 Halle/Saale, Germany.
Department of Internal Medicine IV (Oncology/Hematology), Faculty of Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle/Saale, Germany.
Pharmaceutics. 2021 Sep 23;13(10):1546. doi: 10.3390/pharmaceutics13101546.
The local controlled release of siRNA is an attractive and rational strategy to enhance and extend the effectiveness of gene therapy. Since naked and unmodified siRNA has a limited cell uptake and knockdown efficiency, the complexation of siRNA with non-viral carriers is often necessary for the delivery of bioactive RNA. We evaluated the performance of three different non-viral siRNA carriers, including DOTAP lipoplexes (DL), chitosan polyplexes (CP), and solid lipid complexes (SLC). The physicochemical properties of the siRNA-nanocarriers were characterized by dynamic light scattering and gel electrophoresis. After in vitro characterization, the carrier with the most appropriate properties was found to be the DL suspension, which was subsequently loaded into a gellan gum hydrogel matrix and examined for its drug load, stability, and homogeneity. The hydrogels microstructure was investigated by rheology to assess the impact of the rheological properties on the release of the siRNA nanocarriers. A controlled release of complexed siRNA over 60 days in vitro was observed. By comparing the results from fluorescence imaging with data received from HPLC measurements, fluorescence imaging was found to be an appropriate tool to measure the release of siRNA complexes. Finally, the bioactivity of the siRNA released from hydrogel was tested and compared to free DL for its ability to knockdown the GFP expression in a DLD1 colon cancer cell model. The results indicate controlled release properties and activity of the released siRNA. In conclusion, the developed formulation is a promising system to provide local controlled release of siRNA over several weeks.
siRNA的局部控释是一种增强和延长基因治疗效果的有吸引力且合理的策略。由于裸露且未修饰的siRNA细胞摄取和敲低效率有限,因此siRNA与非病毒载体复合通常是递送生物活性RNA所必需的。我们评估了三种不同的非病毒siRNA载体的性能,包括DOTAP脂质体(DL)、壳聚糖多聚体(CP)和固体脂质复合物(SLC)。通过动态光散射和凝胶电泳对siRNA纳米载体的物理化学性质进行了表征。在体外表征后,发现具有最合适性质的载体是DL悬浮液,随后将其加载到结冷胶水凝胶基质中,并检测其药物负载量、稳定性和均匀性。通过流变学研究水凝胶的微观结构,以评估流变性质对siRNA纳米载体释放的影响。观察到在体外60天内复合siRNA的控释。通过将荧光成像结果与HPLC测量数据进行比较,发现荧光成像是测量siRNA复合物释放的合适工具。最后,测试了从水凝胶中释放的siRNA的生物活性,并将其与游离DL在DLD1结肠癌细胞模型中敲低GFP表达的能力进行了比较。结果表明了释放的siRNA的控释性质和活性。总之,所开发的制剂是一种有前景的系统,可在数周内提供siRNA的局部控释。